Friday, 23 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
Amgen's Imdylltra Gains Conditional Approval in UK for Extensive-Stage Small Cell Lung Cancer
CompanyDrug

Amgen’s Imdylltra Gains Conditional Approval in UK for Extensive-Stage Small Cell Lung Cancer

January 7, 2025
Mabwell Bioscience Files for IPO on Hong Kong Stock Exchange, Expanding Biopharma Reach
CompanyDeals

Mabwell Bioscience Files for IPO on Hong Kong Stock Exchange, Expanding Biopharma Reach

January 7, 2025
WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million
CompanyDeals

WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million

January 7, 2025
Junshi Biosciences' Loqtorzi Gains Regular Approval for Melanoma Treatment in China
CompanyDrug

Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China

January 7, 2025
Simcere Zaiming's SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
CompanyDrug

Simcere Zaiming’s SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

January 7, 2025
NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation
Policy / Regulatory

NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation

January 7, 2025
Huahui Health's HH-003 Gains Priority Review Status for Chronic Hepatitis D Treatment
CompanyDrug

Huahui Health’s HH-003 Gains Priority Review Status for Chronic Hepatitis D Treatment

January 7, 2025
WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager
CompanyDrug

WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager

January 7, 2025
Amoytop Biotech's Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials
CompanyDrug

Amoytop Biotech’s Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials

January 7, 2025
Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making
CompanyDeals

Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making

January 7, 2025
Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization
CompanyDeals

Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization

January 7, 2025
CDE Announces 90th Batch of Reference Preparations for GQCE
Policy / Regulatory

CDE Announces 90th Batch of Reference Preparations for GQCE

January 7, 2025
1 2 … 283 284 285 286 287 … 289 290
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up